Jun 03, 2020
EULAR 2020: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis
Jun 01, 2020
Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Mar 30, 2020
Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Nov 12, 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis
Nov 12, 2019
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Nov 08, 2019
Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting
Oct 12, 2019
Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
Oct 03, 2019
New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis
Sep 11, 2019
AllianceRx Walgreens Prime study demonstrates increased adherence and improvement in symptoms for psoriasis patients switching to interleukin-17 inhibitors
Aug 26, 2019
Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Aug 13, 2019
Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis
Jun 14, 2019
Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
Jun 11, 2019
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
Jun 06, 2019
Lilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology
Jun 05, 2019
Lilly to Showcase Scientific Innovation within Dermatology Portfolio at 24th World Congress of Dermatology
Apr 22, 2019
Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Mar 01, 2019
Lilly to Present Data Demonstrating Continued Scientific Advancements in Broad Dermatology Portfolio at AAD Annual Meeting
Dec 17, 2018
Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Oct 23, 2018
Sun Pharma Announces the Availability of ILUMYA(TM) (tildrakizumab-asmn) in the United States for the Treatment of Moderate-to-Severe Plaque Psoriasis
Oct 22, 2018
ACR 2018: Lilly Announces Positive Results for Two Phase 3 Studies of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)